Literature DB >> 19225717

Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis.

Xue-Ting Shao1, Lei Feng, Li-Juan Gu, Li-Juan Wu, Ting-Ting Feng, Yun-Mei Yang, Nan-Ping Wu, Hang-Ping Yao.   

Abstract

Rheumatoid arthritis (RA) is a chronic immunological disease, the invasive monocytes/macrophages and lymphocytes present in synovial cells and synovial tissue produce many cytokines and inflammatory mediators by paracrine signaling and plays a role in the pathological progress in RA patients. Interleukin-18 (IL-18) is a representative proinflammatory factor and displays multiple biological functions. This study was designed to investigate the expression of IL-18 and its receptor (IL-18R) and IL-18 binding protein (IL-18BP) in serum, synovial fluid, and synovial tissue of patients with RA, and to identify the pathological role of IL-18 in RA. Serum, synovial fluid, and synovial tissue were obtained from RA patients. Samples from patients with osteoarthritis and healthy people were obtained as controls. Levels of IL-18, IL-18BP, and PGE2 in serum and synovial fluid were measured by enzyme-linked immunosorbent assay. The biological activity of IL-18 in serum and synovial fluid was detected on the basis of IFN-gamma secretion from IL-18-responding human myelomonocytic KG-1 cells. NO in serum and synovial fluid was detected by Griess reaction. Expression of IL-18, IL-18BP, IL-18R, iNOS, and COX-2 mRNA and protein in synovial tissues was determined by quantitative reverse transcriptase polymerase chain reaction and Western blot. This study shows the expression levels of IL-18, IL-18R, iNOS, COX-2, and the biological activity of IL-18 in both serum and synovial fluid and tissue of patients with RA were significantly increased compared with the corresponding samples from the two control groups. In addition, expression of IL-18BP in patients with RA was decreased compared with samples from the two control groups. In conclusion, the overexpression of IL-18 and IL-18R may play an important role in the pathogenesis of RA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225717     DOI: 10.1007/s10238-009-0036-2

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  41 in total

1.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18.

Authors:  S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis.

Authors:  C Plater-Zyberk; L A Joosten; M M Helsen; P Sattonnet-Roche; C Siegfried; S Alouani; F A van De Loo; P Graber; S Aloni; R Cirillo; E Lubberts; C A Dinarello; W B van Den Berg; Y Chvatchko
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 3.  Targeting interleukin 18 with interleukin 18 binding protein.

Authors:  C A Dinarello
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

4.  A proinflammatory role for IL-18 in rheumatoid arthritis.

Authors:  J A Gracie; R J Forsey; W L Chan; A Gilmour; B P Leung; M R Greer; K Kennedy; R Carter; X Q Wei; D Xu; M Field; A Foulis; F Y Liew; I B McInnes
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis.

Authors:  B P Leung; I B McInnes; E Esfandiari; X Q Wei; F Y Liew
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

6.  Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.

Authors:  Y Gu; K Kuida; H Tsutsui; G Ku; K Hsiao; M A Fleming; N Hayashi; K Higashino; H Okamura; K Nakanishi; M Kurimoto; T Tanimoto; R A Flavell; V Sato; M W Harding; D J Livingston; M S Su
Journal:  Science       Date:  1997-01-10       Impact factor: 47.728

7.  IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12.

Authors:  K Kohno; J Kataoka; T Ohtsuki; Y Suemoto; I Okamoto; M Usui; M Ikeda; M Kurimoto
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

8.  Regulation of interleukin-18 binding protein production by blood and synovial cells from patients with rheumatoid arthritis.

Authors:  Masanori Kawashima; Daniela Novick; Menachem Rubinstein; Pierre Miossec
Journal:  Arthritis Rheum       Date:  2004-06

9.  Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis.

Authors:  B Bresnihan; P Roux-Lombard; E Murphy; D Kane; O FitzGerald; J-M Dayer
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

10.  Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.

Authors:  Yukiko Komano; Toshihiro Nanki; Kenji Hayashida; Ken Taniguchi; Nobuyuki Miyasaka
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  15 in total

Review 1.  A systems biology approach to synovial joint lubrication in health, injury, and disease.

Authors:  Alexander Y Hui; William J McCarty; Koichi Masuda; Gary S Firestein; Robert L Sah
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2011-08-08

2.  Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation.

Authors:  Anna E Denoble; Kim M Huffman; Thomas V Stabler; Susan J Kelly; Michael S Hershfield; Gary E McDaniel; R Edward Coleman; Virginia B Kraus
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-18       Impact factor: 11.205

3.  Blocking ERK-1/2 reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A.

Authors:  Hubert Marotte; Salahuddin Ahmed; Jeffrey H Ruth; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2010-03

4.  Construction of a recombinant adenovirus vector expressing IL-18BP/IL-4 fusion gene and the anti-inflammatory effect induced by this gene on lipopolysaccharide-stimulated synovial fibroblasts.

Authors:  Hang-Ping Yao; Yun Qian; Xue-Ting Shao; Zhe-Rong Xu; Lin-Fang Cheng; Lei Feng; Nan-Ping Wu; Yun-Mei Yang
Journal:  Inflamm Res       Date:  2009-11-22       Impact factor: 4.575

5.  Association of IL-18 promoter gene polymorphisms with rheumatoid arthritis: a meta-analysis.

Authors:  Li-Ping Cai; Li-Juan Zhou; Shun-Yu Lu; Ying-E Liang; Xiao-Ying Chen; Lin Liu; Jun Lin
Journal:  Mol Biol Rep       Date:  2014-09-06       Impact factor: 2.316

6.  An Association Study of Interleukin 18 Receptor Genes (IL18R1 and IL18RAP) in Lumbar Disc Degeneration.

Authors:  Ahmad Omair; Benedicte Alexandra Lie; Olav Reikeras; Jens Ivar Brox
Journal:  Open Orthop J       Date:  2012-04-20

7.  Caspase-1 level in synovial fluid is high in patients with spondyloarthropathy but not in patients with gout.

Authors:  Chang-Nam Son; So-Young Bang; Ji Hae Kim; Chan-Bum Choi; Tae-Hwan Kim; Jae-Bum Jun
Journal:  J Korean Med Sci       Date:  2013-08-28       Impact factor: 2.153

Review 8.  The role of nucleotides and purinergic signaling in apoptotic cell clearance - implications for chronic inflammatory diseases.

Authors:  Jin Chen; Yi Zhao; Yi Liu
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561

9.  Enhanced Expression of IL-18 and IL-18BP in Plasma of Patients with Eczema: Altered Expression of IL-18BP and IL-18 Receptor on Mast Cells.

Authors:  Yalin Hu; Junling Wang; Huiyun Zhang; Hua Xie; Weiwei Song; Qijun Jiang; Nan Zhao; Shaoheng He
Journal:  Mediators Inflamm       Date:  2017-08-03       Impact factor: 4.711

10.  Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.

Authors:  Carl K Edwards; Julie S Green; Hans-Dieter Volk; Michael Schiff; Brian L Kotzin; Hiroaki Mitsuya; Tatsuya Kawaguchi; Ken-Mei Sakata; John Cheronis; David Trollinger; Danute Bankaitis-Davis; Charles A Dinarello; David A Norris; Michael P Bevilacqua; Mayumi Fujita; Gerd-Rudiger Burmester
Journal:  Front Immunol       Date:  2012-12-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.